Showing results (101-110 of 237) with videos related to
Sort By:
Pageof 24
Diabetes, Obesity & Metabolism|February 14, 2019
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitusJoanna Parkinson, Weifeng Tang, Magnus Åstrand, et al.Clinical Pharmacology in Drug Development|May 4, 2016
Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailabilityTjerk W A de Bruin, Stots Reele, Jennifer E Hamer-Maansson, et al.Chemosphere|December 15, 2024
Urinary concentrations of eighteen environmental phenols and the associations with feeding pattern in infants in the first 6 months of lifeLi Shu, Pianpian Fan, Yuanzhi Chen, et al.Clinical Pharmacology and Therapeutics|May 23, 2026
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus NephritisJoachim Almquist, Yen Lin Chia, Raj Tummala, et al.CPT: Pharmacometrics & Systems Pharmacology|March 13, 2023
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetesVictor Sokolov, Tatiana Yakovleva, Leonid Stolbov, et al.Clinical Pharmacokinetics|May 6, 2023
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of AnifrolumabWeifeng Tang, Raj Tummala, Joachim Almquist, et al.British Journal of Clinical Pharmacology|May 12, 2019
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitusDavid Busse, Weifeng Tang, Markus Scheerer, et al.Environmental Pollution (Barking, Essex : 1987)|July 25, 2018
2,2',4,4'-tetrabromodiphenyl ether induces germ cell apoptosis through oxidative stress by a MAPK-mediated p53-independent pathwayXinyue You, Jing Xi, Weiying Liu, et al.Journal of Clinical Pharmacology|April 11, 2022
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes MellitusJohanna Melin, Weifeng Tang, Dinko Rekić, et al.Oncotarget|May 11, 2017
Programmed death-1 polymorphisms is associated with risk of esophagogastric junction adenocarcinoma in the Chinese Han population: A case-control study involving 2,740 subjectsWeifeng Tang, Shuchen Chen, Yu Chen, et al.Pageof 24